Codiak BioSciences, Inc.

CDAK

Explore Our Financial Data > Companies > Small Cap > Codiak BioSciences, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
CDAK
CIK0001659352
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE, MA, 02140
Website codiakbio.com
Phone617-949-4100
CEODouglas E. Williams
Employees100

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$34.07 million
Pre-Tax Income$-17.43 million
Net Income$-17.42 million
Net Income to Common$-17.42 million
EPS$-0.66
View All
Balance Sheet
Cash$51.76 million
Assets$134.40 million
Liabilities$95.47 million
Common Equity$38.93 million
Liabilities & Equity$134.40 million
View All
Cash Flow Statement
Net Income$-17.42 million
Cash From Operating Activities$-67.08 million
Cash From Investing Activities$-694,000.00
Cash From Financing Activities$20.95 million
Change in Cash$-46.82 million
View All
Calculations
NOPAT$-37.31 million
EBITDA$-10.66 million
Price to EarningsN/A
Price to Book$0.04
ROE-47.77%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Codiak BioSciences Files For Chapter 11 Bankruptcy

Codiak BioSciences Inc (NASDAQ: CDAK) voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets. The company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The company expects to consummate a sale of the entire business or its core assets. Codiak BioScien

Article Link

Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value o

Article Link

Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak’s Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Co

Article Link

Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with a

Article Link

Codiak BioSciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Codiak BioSciences ( NASDAQ:CDAK ) Third Quarter 2022 Results Key Financial Results Revenue: US$522.0k (down 55% from...

Article Link